Document is current

Article History

Received: 22 December 2020

Accepted: 12 March 2021

First Online: 8 April 2021

Declarations

:

: Not applicable.

: Not applicable.

: Louise Carlsen has lectured for Allergan and TEVA and serves on an advisory board for Lundbeck. Faisal M. Amin has received lecturing fee or participated in advisory boards for TEVA, Eli Lilly, Lundbeck and Novartis. Faisal M. Amin is principal investigator for phase 4 trials for TEVA and Novartis. Faisal M. Amin is the current president of the Danish Headache Society, and serve as associate editor for Headache Medicine and Frontiers in Pain Research. Rigmor H. Jensen is or has been principal investigator in studies sponsored by Lundbeck, Eli Lilly and ATI and has given lectures for Novartis, Lundbeck, Allergan, TEVA and ATI. Messoud Ashina is a consultant, speaker, or scientific advisor for AbbVie, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva; primary investigator for AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva trials. Messoud Ashina serves as associate editor of Cephalalgia; associate editor of Headache; associate editor of the Journal of Headache and Pain. Messoud Ashina is President of the International Headache Society. Nunu Lund has given lectures for laegekurser.dk and ABG Investment. Lars Bendtsen has served on the scientific advisory board for Novartis, Allergan, Teva, Lundbeck and Eli Lilly. Henrik W. Schytz has served on scientific advisory board for Lundbeck and Eli Lilly and has received lecturing fee from TEVA and Novartis. Henrik W. Schytz has received research grants from Novartis. Lars Poulsen, Dagmar Beier, Karen Aegidius, Lise L. Thomsen, Flemming W. Bach, Hanne Johansen, Jakob M. Hansen, Helge Kasch, Signe B. Munksgaard, Lars Poulsen, Peter T. Schmidt-Hansen and Vlasta V. Cvetkovic reports no conflicts of interest.